Advantages of NMNH
NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity（up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
Advantages of NADH
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
Advantages of NAD
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
Advantages of MNM
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity（up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
We Have The Best Solutions for Your Business
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
NADH powder manufacturing method
The main methods of NADH powder preparation include extraction, fermentation, fortification, biosynthesis and organic matter synthesis. Compared with other preparations, the whole enzyme become the mainstream method owing to the advantages of pollution free, high level of purity and stability.
BONTAC NADH product features and advantages
1、“Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder
2、Exclusive“Bonpure” seven-step purification technology, high purity（up to 99%) and stability of production of NADH powder
3、Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMN powder
4、Provide one-stop product solution customization service
NADH powder efficacy in health
Improved energy levels
Not only does NADH act as an important coenzyme in aerobic respiration, the [H] of NADH also carries a large amount of energy. Studies have demonstrated that extracellular use of NADH promotes increased intracellular ATP levels, suggesting that NADH penetrates cell membranes and elevates intracellular energy levels. On a macro level, exogenous supplementation of NADH helps to restore energy and enhance appetite. The increase in energy levels in the brain also helps to improve mental performance and sleep quality. NADH has been used overseas to improve chronic fatigue syndrome, increase exercise endurance, jet lag and other areas.
Cellular protection
NADH is a strong antioxidant that naturally occurs in cells and reacts with free radicals to inhibit lipid peroxidation, protecting mitochondrial membranes and mitochondrial function. It has been found that NADH can reduce oxidative stress in cells caused by various factors such as radiation, drugs, toxic substances, strenuous exercise and ischemia, thus protecting vascular endothelial cells, hepatocytes, cardiomyocytes, fibroblasts and neurons. Therefore, injectable or oral NADH is used clinically to improve cardiovascular and cerebrovascular diseases, and as an adjunct to cancer radiotherapy. Topical NADH has been shown to be effective in the treatment of rosacea and contact dermatitis.
Promotion of neurotransmitter production
Studies have shown that NADH significantly promotes the production of the neurotransmitter dopamine, a chemical signal that is essential for short-term memory, involuntary movements, muscle tone and spontaneous physical responses. It also mediates the release of growth hormone and determines muscle movement. Without sufficient dopamine, muscles become stiff. Parkinson's disease, for example, is caused in part by a disruption of dopamine synthesis in brain cells. Preliminary clinical data suggest that NADH can help improve the symptoms of Parkinson's disease [9]. NADH also promotes the biosynthesis of norepinephrine and serotonin, showing good potential for use in the relief of depression and Alzheimer's disease.
User Reviews
What users say about BONTAC
Frequently Asked Question
Do you have any question?
NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.
The action of supplemental NADH is unclear. Oral NADH supplementation has been used to combat simple fatigue as well as such mysterious and energy-sapping disorders as chronic fatigue syndrome and fibromyalgia. Researchers are also studying the value of NADH supplements for improving mental function in people with Alzheimer's disease, and minimizing physical disability and relieving depression in people with Parkinson's disease. Some healthy individuals also take NADH supplements orally to improve concentration and memory capacity, as well as to increase athletic endurance. However, to date there have been no published studies to indicate that using NADH is in any way effective or safe for these purposes
First, inspect the factory. After some screening, NADH companies that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NADH powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMN cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NADH powder produced by Bontac reach the purity of 99%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
Our updates and blog posts
Tailoring Personalized Dosage Regimens of NMN Based on NAD Concentration
Introduction Nicotinamide mononucleotide (NMN), one precursor of nicotinamide adenine dinucleotide (NAD+), has been ascertained to be implicated with multiple biological processes such as cellular redox regulation and metabolism as well as DNA repair. Herein, post-hoc analysis of a double-blinded clinical trial is carried out. On the premise of safety, to optimize NMN utilization, personalized dosage regimen can be developed by monitoring the NAD concentration. Research protocol A total of 80 healthy middle-aged adults (age: 40 to 65) are enrolled in the randomized, double-blinded, controlled clinical trial of NMN supplementation, who are randomly assigned into four groups and administrated with placebo or NMN (300 mg, 600 mg, or 900 mg) for 60 days. The clinical data including age, sex, body mass index (BMI), blood biological age, homeostatic model assessment for insulin resistance (HOMA-IR), blood NAD concentration, 6-minute walk test and 36-item short-form survey (SF-36), along with adverse events, are collected at baseline and after supplement, followed by comparison and correlation analysis. The association of participant clinical data at baseline and after supplement of NMN NAD concentration change (NADΔ) is dose-dependently increased post NMN supplementation, with a large coefficient of variation (29.2–113.3%) within group. Notably, only HOMA-IR has a prominent association with blood baseline NAD. As a whole, NMN supplementation has a positive impact on the physical endurance and general health conditions of healthy adults, as evidenced by the obvious improvement of six-minute walking distance, blood biological age, and SF-36 score. In addition, the increase of about 15 nmol/L in NADΔ is related to clinically improvements in the walking distance of 6-minute walk test and the SF-36 score. The safety oral dose of NMN in clinical trials As demonstrated by the registered clinical trials NCT04823260 and CTRI/2021/03/032421, NMN supplementation can boost blood NAD concentration, which is safe and well tolerated with daily oral administration of 900 mg. Strikingly, clinical efficacy expressed by blood NAD concentration and physical performance reaches highest at a dose of 600 mg daily oral intake. Conclusion Blood NAD concentration is increased by NMN supplement at a dose-dependent manner. Personalized regimen of NMN supplement should be based on the close monitoring of NAD concentration change. In addition to longer follow-up duration and large sample size, future trials on the efficacy of NMN supplement should pay much attention to the factors affecting baseline NAD concentration. Reference [1] Kuerec AH, Wang W, Yi L, et al. Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration. Mech Ageing Dev. 2024;218:111917. doi:10.1016/j.mad.2024.111917 [2] Song Q, Zhou X, Xu K, Liu S, Zhu X, Yang J. The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Adv Nutr. 2023;14(6):1416-1435. doi:10.1016/j.advnut.2023.08.008 BONTAC NMN As David Sinclair, a famous professor of genetics at Harvard University, once pointed out in an interview, NMN has unstable molecular structure, which is easily degraded into nicotinamide if stored in the conventional environment. The satisfactory efficacy of NMN cannot be guaranteed if the quality and purity NMN products are not high. BONTAC is the first choice of NMN raw material suppliers worldwide, who has dedicated to the manufacture of raw material for enzyme and natural products for 12 years, with self-owned factory, 173 patents and professional R&D team. The purity of BONTAC NMN can reach up to 99.5%. Also, BONTAC is the NMN raw material supplier of David Sinclair team, who uses the raw materials of BONTAC in a paper titled “Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging”. Our services and products have been highly recognized by global partners. The coenzyme products of BONTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Supplementing NAD+ precursors as a promising approach for DPN
1. Introduction Diabetic peripheral neuropathy (DPN) is one of the most frequent complications of diabetes, ans also a major cause of foot ulcers, disability, and eventual amputation. With the prolongation of the diabetes, about 50% of people with diabetes will eventually develop DPN. Notably, supplementing NAD+ precursors could alleviate DPN symptoms by increasing the NAD+ level and activating the sirtuin-1 (SIRT1) protein. 2. The reversal effect of NAD+ precursors on DPN In vitro, the Dorsal Root Ganglion neurons (DRGs) isolated from diabetic mice are exposed to the NAD+ precursor Nicotinamide Riboside (NR) or Nicotinamide Mononucleotide (NMN). It is found that the NAD+ level, the SIRT1 protein, and the deacetylation activity are elevated, followed by the boosted neurite growth, the improved nerve function, and the reversal of IENFD loss. In vivo, supplement of NMN or NR also offsets the neuropathy in C57BL6 mice induced by streptozotocin (STZ) or high fat diet (HFD), as manifested by the improved sensory function, normalized nerve conduction velocities, and restored intraepidermal nerve fibers. 3. The increase of neurite length in a SIRT1-dependent manner post the addition of NMN/NR SIRT1, one of the most unique NAD+ consuming enzymes, can protect against DPN when activated, which may attribute to the improved mitochondrial function and energy homeostasis. Apart from these, SIRT1 activity in the nucleus can deacetylate the transcriptional and co-transcriptional factors that regulate glucose homeostasis and fat oxidation. The activation of SIRT1 is critical for axonal regeneration. NMN/NR treatment or transfection with SIRT1 overexpression vector can directly facilitate the neurite growth in cultured DRG neurons, which however is hindered by the SIRT1 inhibitor EX527, hinting the significance of SIRT1. 4. The association of SARM1 with NMNAT2 in axonal degeneration of DPN Sterile alpha and Toll/interleukin-1 receptor motif-containing 1 (SARM1) controls the axonal degeneration and regeneration via a well-regulated system comprising NAD+ and NMN. NAD and NMNAT2 can boost vesicular glycolysis and axonal transport to maintain the axonal health. The mitochondrial localization of SARM1 complements the coordinated activity of NMNAT2 that promotes axonal survival. 5. Conclusion Supplementing NAD+ precursors may be a promising approach for the treatment of DPN. A SARM1 inhibitor coupled with either NR or NMN may be more effective than a single agent alone in preventing or treating DPN. Reference Chandrasekaran K, Najimi N, Sagi AR, et al. NAD+ Precursors Reverse Experimental Diabetic Neuropathy in Mice. Int J Mol Sci. 2024;25(2):1102. Published 2024 Jan 16. doi:10.3390/ijms25021102 BONTAC NMN and NR BONTAC has dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 160 global patents as well as strong R&D team consisting of Doctors and Masters. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. Both the precursors NMN and NR are available in BONTAC. The high purity and stability of products can be better ensured here with the exclusive Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Bontac makes it to KPMG's China Biotech Innovation Enterprises Top 50
On April 7th, 2023, KPMG China hosted the second Biotech Innovation 50 Enterprises award ceremony online, with CITIC Securities as a co-organizer. Bontac impressed the panel with its strong R&D capabilities and excellent performance in the synthetic biology sector, earning a spot on the "KPMG China 2023 Biotech Innovation Enterprises Top 50" list. The experts panel spent six months selecting the winners based on five core criteria: technology and product leadership, product pipeline richness and original research ratio, core management and R&D team background, capital market activity, and financial health. Bontac shines with its solid strength The "KPMG China 2023 Biotech Innovation Enterprises Top 50" award evaluated the enterprises from various aspects such as products, technology, team, finance, and funding. The selected enterprises are all high-quality enterprises with outstanding abilities in the biotech field, and being on the list is a great recognition. Bontac Deputy (fourth from the left) Bontac, as a leader in the synthetic biology industry, has always been at the forefront of R&D and production of coenzymes such as NMN, NADH and natural products such as ginsenoside Rh2, stevioside RD, etc. It has a strong comprehensive strength and a promising development potential that won the unanimous approval of the experts panel. From a scientific and technological point of view, Bontac has overcome several technical challenges, obtained more than 160 international patents and over 10 honorary qualifications, and owns more than 600 proprietary enzyme libraries. From the perspective of business scale, Bontac has three production bases that can achieve industrial production of hundreds of tons annually. Bontac also serves customers in more than 20 provinces in China and more than 60 countries. With the accordance of team configuration , Bontac has assembled representatives from four sides: scientists, engineers, entrepreneurs, and investors, empowering the enterprise from multiple dimensions. With the continuous upgrade of health consumption, the gradual release of new policy benefits related to medical regulation, and the rapid development of biopharmaceutical technology industry from a high-tech industry with great potential to a high-tech pillar industry. Biotech enterprises with potential represented by Bontac will leverage policy advantages and ride on market opportunities to integrate diverse resources in the ecosystem, support the development of China's biotech innovation enterprises, and enable win-win cooperation for the entire ecosystem. KPMG Biotech Innovation Enterprises Top 50 KPMG Awarding Ceremony KPMG China launched its first "Biotech Innovation Enterprises Top 50" award in 2021 and received widespread attention and support from the industry. KPMG invited distinguished representatives from research, industry, investment, and enterprise fields to share their insights on the hot topics and trends in biotech and explore the best practices for biotech innovation enterprises. The award also created a resource-matching platform for the selected biotech enterprises with potential, helping them seize the policy direction and capital market opportunities, increase their market visibility, and achieve organic growth from within and outside.